-
Mashup Score: 3
: Optimal treatment strategies for patients with hepatocellular carcinoma (HCC) with oligoprogression after first-line systemic therapy (FLST) remain undefined. We aimed to determine if maintaining [i.e., continuing] FLST plus radiotherapy for oligoprogressive lesions (m-FLST + RT) would result in progression-free survival (PFS) equal to or greater than that of second-line systemic therapy (s-SLST), either alone or with radiotherapy (s-SLST + RT).
Source: www.redjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 12The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma - PubMed - 3 month(s) ago
Isocitrate dehydrogenase (IDH)-mutant gliomas are the most common malignant primary brain tumors in young adults. This condition imposes a substantial burden on patients and their caregivers, marked by neurocognitive deficits and high mortality rates due to tumor progression, coupled with significan …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
RT @gminniti2012: A comprehensive review on The role of vorasidenib in the treatment of IDH-mutant glioma https://t.co/LDN4k7hYFw New trial…
-
-
Mashup Score: 3CAR-T cell therapy for the treatment of adult high-grade gliomas - 3 month(s) ago
npj Precision Oncology – CAR-T cell therapy for the treatment of adult high-grade gliomas
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
RT @braintumor: Nice review by @BryanDChoi and team @MassGeneralNews https://t.co/2bQ98bLtoL
-
-
Mashup Score: 13
We observed improved overall survival compared with historical controls and a promising adverse event profile by using 18F-DOPA PET−guided, dose-escalated, hypofractionated proton beam therapy. These findings have resulted in the opening of a phase 2 study (NCT05781321) investigating this regimen versus standard-of-care treatment in adults of any age with newly diagnosed glioblastoma.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
RT @PDBrownOnc: Phase II trial hypofractionated proton beam therapy, F-DOPA elderly GBM https://t.co/FiSrbJmJ3b
-
-
Mashup Score: 13
We observed improved overall survival compared with historical controls and a promising adverse event profile by using 18F-DOPA PET−guided, dose-escalated, hypofractionated proton beam therapy. These findings have resulted in the opening of a phase 2 study (NCT05781321) investigating this regimen versus standard-of-care treatment in adults of any age with newly diagnosed glioblastoma.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
RT @PDBrownOnc: Phase II trial hypofractionated proton beam therapy, F-DOPA elderly GBM https://t.co/FiSrbJmJ3b
-
-
Mashup Score: 568Ga-DOTATATE PET to Characterize Lesions in the Neuroaxis : Clinical Nuclear Medicine - 4 month(s) ago
his retrospective study considered 70 neuroaxis lesions in 52 patients with 68Ga-DOTATATE PET/CT examinations; 22 lesions (31%) had pathologic confirmation. Lesions were grouped based on pathological diagnosis and best radiologic diagnosis when pathology was not available. Wilcoxon rank sum tests were used to test for differences in SUVmax among paragangliomas, schwannomas, and meningiomas. Receiver operator characteristic curves were constructed. Results Paragangliomas had a significantly greater 68Ga-DOTATATE uptake (median SUVmax, 62; interquartile range [IQR], 89) than nonparagangliomas. Schwannomas had near-zero 68Ga-DOTATATE uptake (median SUVmax, 2; IQR, 1). Intermediate 68Ga-DOTATATE uptake was seen for meningiomas (median SUVmax, 19; IQR, 6) and other neuroaxis lesions (median SUVmax, 7; IQR, 9). Receiver operator characteristic analysis demonstrated an area under the curve of 0.87 for paragangliomas versus all other lesions and 0.97 for schwannomas versus all other lesions. C
Source: journals.lww.comCategories: General Medicine News, Hem/OncsTweet-
RT @ClinNuclearMed: Current Issue: 68Ga-DOTATATE PET to Characterize Lesions in the Neuroaxis https://t.co/S4Al4GAoGR
-
-
Mashup Score: 1
The management of recurrent glioblastoma remains a clinical challenge with a dearth of effective treatment options and a dismal prognosis.1 While surgery,
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet-
RT @NMNSymposium: Point/Counterpoint: The role of #reirradiation in recurrent #glioblastoma. https://t.co/OtzAY8r2qP #btsm #radiotherapy…
-
-
Mashup Score: 66The danger theory of immunity revisited - 4 month(s) ago
Nature Reviews Immunology – Thirty years ago, Polly Matzinger introduced the ‘danger theory of immunity’, which proposed that danger and damage have a decisive role in immune responses….
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
RT @LabWaggoner: REVIEW @NatRevImmunol The danger theory of immunity revisited https://t.co/Yyp8tNLaCw
-
-
Mashup Score: 1The Immune Landscape in Brain Metastasis - 5 month(s) ago
Abstract. The prognosis for patients with brain metastasis remains dismal despite intensive therapy including surgical resection, radiotherapy, chemo-, tar
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet-
RT @NMNSymposium: Immune Landscape in Brain Metastasis. https://t.co/9IvoUVmfsS #btsm @NeuroOnc @EANOassociation
-
-
Mashup Score: 27Mutant ARID1A: igniting cancer immunotherapy - 7 month(s) ago
Maxwell et al. show that ARID1A loss enhances antitumor immunity by triggering a type I IFN response through the cGAS–STING pathway, thereby promoting T cell infiltration and cytotoxicity. These findings highlight SWI/SNF inhibitors as a strategy to augment immunotherapy efficacy by potentially transforming non-responsive tumors into responders and advancing approaches to cancer treatment.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet-
RT @TrendsImmuno: Mutant ARID1A: igniting cancer immunotherapy https://t.co/YjXD4ByUN8 #immunology https://t.co/4RlX6RhJWy
-
RT @gusviani: https://t.co/6SD6yGJcIj